Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).

Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AM.

Clin Cancer Res. 2020 Jan 28. pii: clincanres.2576.2019. doi: 10.1158/1078-0432.CCR-19-2576. [Epub ahead of print]

PMID:
31992589
2.

Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.

Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO, Hogg D, Sacher A, Oza AM, Al-Agha R, Maurice C, Chan CT, Shapera S, Feld JJ, Nisenbaum R, Webster K, Cella D, Parsons J.

Cancer. 2020 Jan 8. doi: 10.1002/cncr.32692. [Epub ahead of print]

PMID:
31914209
3.

GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.

Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TDS, Ugel S, Tsirigos A, Bronte V, Munn DH, Pugh TJ, De Carvalho DD, Butler MO, Ohashi PS, Brooks DG, McGaha TL.

Sci Immunol. 2019 Dec 13;4(42). pii: eaax8189. doi: 10.1126/sciimmunol.aax8189.

PMID:
31836669
4.

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).

Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK.

Clin Cancer Res. 2020 Feb 15;26(4):804-811. doi: 10.1158/1078-0432.CCR-19-1223. Epub 2019 Sep 26.

PMID:
31558480
5.

Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.

Saibil SD, Bonilla L, Majeed H, Sotov V, Hogg D, Chappell MA, Cybulsky M, Butler MO.

Curr Oncol. 2019 Jun;26(3):e418-e421. doi: 10.3747/co.26.4381. Epub 2019 Jun 1.

6.

Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87.

Anczurowski M, Sugata K, Matsunaga Y, Yamashita Y, Wang CH, Guo T, Murata K, Saijo H, Kagoya Y, Saso K, Butler MO, Hirano N.

J Autoimmun. 2019 Aug;102:114-125. doi: 10.1016/j.jaut.2019.04.023. Epub 2019 May 8.

PMID:
31078377
7.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.

8.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM.

Gynecol Oncol. 2019 May;153(2):304-311. doi: 10.1016/j.ygyno.2019.02.005. Epub 2019 Feb 18.

PMID:
30792002
9.

Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.

Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL.

Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15.

PMID:
30768786
10.

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.

Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, Leong W, Easson A, Reedijk M, Goldstein DP, McCready D, Yasufuku K, Waddell T, Cypel M, Pierre A, Zhang B, Boross-Harmer S, Cipollone J, Nelles M, Scheid E, Fyrsta M, Lo CS, Nie J, Yam JY, Yen PH, Gray D, Motta V, Elford AR, DeLuca S, Wang L, Effendi S, Ellenchery R, Hirano N, Ohashi PS, Butler MO.

Cancer Immunol Immunother. 2019 May;68(5):773-785. doi: 10.1007/s00262-019-02307-x. Epub 2019 Feb 11.

PMID:
30747243
11.

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses.

Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S.

Int J Gynecol Cancer. 2019 Jan 18. pii: ijgc-2018-000087. doi: 10.1136/ijgc-2018-000087. [Epub ahead of print]

PMID:
30659026
12.

CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling.

Mulder DT, Mahé ER, Dowar M, Hanna Y, Li T, Nguyen LT, Butler MO, Hirano N, Delabie J, Ohashi PS, Pugh TJ.

Blood Adv. 2018 Dec 11;2(23):3506-3514. doi: 10.1182/bloodadvances.2017014639. Erratum in: Blood Adv. 2019 Jan 22;3(2):121.

13.

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A.

Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7.

PMID:
30529898
14.

Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells.

Kagoya Y, Saijo H, Matsunaga Y, Guo T, Saso K, Anczurowski M, Wang CH, Sugata K, Murata K, Butler MO, Arrowsmith CH, Hirano N.

J Autoimmun. 2019 Feb;97:10-21. doi: 10.1016/j.jaut.2018.09.011. Epub 2018 Oct 11.

PMID:
30318155
15.

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.

Lheureux S, Tinker A, Clarke B, Ghatage P, Welch S, Weberpals JI, Dhani NC, Butler MO, Tonkin K, Tan Q, Tan DSP, Brooks K, Ramsahai J, Wang L, Pham NA, Shaw PA, Tsao MS, Garg S, Stockley T, Oza AM.

Clin Cancer Res. 2018 Dec 15;24(24):6168-6174. doi: 10.1158/1078-0432.CCR-18-1244. Epub 2018 Aug 14.

16.

Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.

Lewin J, Davidson S, Anderson ND, Lau BY, Kelly J, Tabori U, Salah S, Butler MO, Aung KL, Shlien A, Dickson BC, Abdul Razak AR.

Cancer Immunol Res. 2018 Sep;6(9):1001-1007. doi: 10.1158/2326-6066.CIR-18-0037. Epub 2018 Jul 17.

17.

DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.

Kagoya Y, Nakatsugawa M, Saso K, Guo T, Anczurowski M, Wang CH, Butler MO, Arrowsmith CH, Hirano N.

Nat Commun. 2018 May 15;9(1):1915. doi: 10.1038/s41467-018-04262-0.

18.

Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly.

Anczurowski M, Yamashita Y, Nakatsugawa M, Ochi T, Kagoya Y, Guo T, Wang CH, Rahman MA, Saso K, Butler MO, Hirano N.

Sci Rep. 2018 Mar 19;8(1):4804. doi: 10.1038/s41598-018-22931-4.

19.

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.

Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD, Hirano N.

Nat Med. 2018 Mar;24(3):352-359. doi: 10.1038/nm.4478. Epub 2018 Feb 5.

20.

A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs.

Guo T, Koo MY, Kagoya Y, Anczurowski M, Wang CH, Saso K, Butler MO, Hirano N.

J Immunol. 2018 Jan 15;200(2):500-511. doi: 10.4049/jimmunol.1700677. Epub 2017 Dec 13.

21.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.

Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM.

JAMA Oncol. 2018 Jul 12;4(7):e173776. doi: 10.1001/jamaoncol.2017.3776. Epub 2018 Jul 12.

22.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.

23.

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.

Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL, Chow LQM.

Clin Cancer Res. 2017 Sep 1;23(17):4992-5002. doi: 10.1158/1078-0432.CCR-16-3066.

24.

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Day D, Monjazeb AM, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO.

Clin Cancer Res. 2017 Sep 1;23(17):4980-4991. doi: 10.1158/1078-0432.CCR-16-3064.

25.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

26.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

27.

HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway.

Yamashita Y, Anczurowski M, Nakatsugawa M, Tanaka M, Kagoya Y, Sinha A, Chamoto K, Ochi T, Guo T, Saso K, Butler MO, Minden MD, Kislinger T, Hirano N.

Nat Commun. 2017 May 10;8:15244. doi: 10.1038/ncomms15244.

28.

Correction: Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.

Chamoto K, Guo T, Scally SW, Kagoya Y, Anczurowski M, Wang CH, Rahman MA, Saso K, Butler MO, Chiu PPL, Julien JP, Hirano N.

J Immunol. 2017 May 1;198(9):3757. doi: 10.4049/jimmunol.1700296. No abstract available.

29.

Transient stimulation expands superior antitumor T cells for adoptive therapy.

Kagoya Y, Nakatsugawa M, Ochi T, Cen Y, Guo T, Anczurowski M, Saso K, Butler MO, Hirano N.

JCI Insight. 2017 Jan 26;2(2):e89580. doi: 10.1172/jci.insight.89580.

30.

Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.

Chamoto K, Guo T, Scally SW, Kagoya Y, Anczurowski M, Wang CH, Rahman MA, Saso K, Butler MO, Chiu PP, Julien JP, Hirano N.

J Immunol. 2017 Feb 1;198(3):1056-1065. doi: 10.4049/jimmunol.1601556. Epub 2016 Dec 21. Erratum in: J Immunol. 2017 May 1;198(9):3757.

31.

Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain.

Guo T, Ochi T, Nakatsugawa M, Kagoya Y, Anczurowski M, Wang CH, Rahman MA, Saso K, Butler MO, Hirano N.

J Vis Exp. 2016 Oct 25;(116). doi: 10.3791/54697.

32.

The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.

Khoja L, Atenafu EG, Templeton A, Qye Y, Chappell MA, Saibil S, Hogg D, Butler MO, Joshua AM.

Cancer Med. 2016 Oct;5(10):2792-2799. doi: 10.1002/cam4.878. Epub 2016 Sep 29.

33.

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.

Khoja L, Kibiro M, Metser U, Gedye C, Hogg D, Butler MO, Atenafu EG, Joshua AM.

Br J Cancer. 2016 Nov 8;115(10):1186-1192. doi: 10.1038/bjc.2016.308. Epub 2016 Oct 4.

34.

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models.

Kagoya Y, Nakatsugawa M, Yamashita Y, Ochi T, Guo T, Anczurowski M, Saso K, Butler MO, Arrowsmith CH, Hirano N.

J Clin Invest. 2016 Sep 1;126(9):3479-94. doi: 10.1172/JCI86437. Epub 2016 Aug 22.

35.

Effect of Chlorhexidine Bathing Every Other Day on Prevention of Hospital-Acquired Infections in the Surgical ICU: A Single-Center, Randomized Controlled Trial.

Swan JT, Ashton CM, Bui LN, Pham VP, Shirkey BA, Blackshear JE, Bersamin JB, Pomer RM, Johnson ML, Magtoto AD, Butler MO, Tran SK, Sanchez LR, Patel JG, Ochoa RA Jr, Hai SA, Denison KI, Graviss EA, Wray NP.

Crit Care Med. 2016 Oct;44(10):1822-32. doi: 10.1097/CCM.0000000000001820.

PMID:
27428384
36.

Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors.

Guo T, Chamoto K, Nakatsugawa M, Ochi T, Yamashita Y, Anczurowski M, Butler MO, Hirano N.

PLoS One. 2016 May 23;11(5):e0156114. doi: 10.1371/journal.pone.0156114. eCollection 2016.

37.

Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.

Fiset PO, Shapera S, Butler MO, Tsao MS.

Ann Oncol. 2016 Aug;27(8):1649-50. doi: 10.1093/annonc/mdw178. Epub 2016 Apr 18. No abstract available.

38.

CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells.

Nakatsugawa M, Rahman MA, Yamashita Y, Ochi T, Wnuk P, Tanaka S, Chamoto K, Kagoya Y, Saso K, Guo T, Anczurowski M, Butler MO, Hirano N.

Sci Rep. 2016 Mar 31;6:23821. doi: 10.1038/srep23821.

39.

Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.

Khoja L, Atenafu EG, Ye Q, Gedye C, Chappell M, Hogg D, Butler MO, Joshua AM.

Oncol Lett. 2016 Feb;11(2):1581-1585. Epub 2015 Dec 31.

40.

Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma.

Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N, Butler MO, Rogalla P, Mason W, Joshua AM, Hogg D.

Cancer Immunol Res. 2016 Mar;4(3):175-8. doi: 10.1158/2326-6066.CIR-15-0186. Epub 2016 Jan 28.

41.

CDR3β sequence motifs regulate autoreactivity of human invariant NKT cell receptors.

Chamoto K, Guo T, Imataki O, Tanaka M, Nakatsugawa M, Ochi T, Yamashita Y, Saito AM, Saito TI, Butler MO, Hirano N.

J Autoimmun. 2016 Apr;68:39-51. doi: 10.1016/j.jaut.2015.12.005. Epub 2015 Dec 31.

42.

Increased treatment-related toxicity subsequent to an anti-PD-1 agent.

Khoja L, Butler MO, Chappell MA, Hogg D, Joshua AM.

Curr Oncol. 2015 Aug;22(4):e320-2. doi: 10.3747/co.22.2418. No abstract available.

43.

Pembrolizumab.

Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM.

J Immunother Cancer. 2015 Aug 18;3:36. doi: 10.1186/s40425-015-0078-9. eCollection 2015. Review.

44.

Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.

Ochi T, Nakatsugawa M, Chamoto K, Tanaka S, Yamashita Y, Guo T, Fujiwara H, Yasukawa M, Butler MO, Hirano N.

Cancer Immunol Res. 2015 Sep;3(9):1070-81. doi: 10.1158/2326-6066.CIR-14-0222. Epub 2015 May 5.

45.

Specific roles of each TCR hemichain in generating functional chain-centric TCR.

Nakatsugawa M, Yamashita Y, Ochi T, Tanaka S, Chamoto K, Guo T, Butler MO, Hirano N.

J Immunol. 2015 Apr 1;194(7):3487-500. doi: 10.4049/jimmunol.1401717. Epub 2015 Feb 20.

46.

Provider barriers prevent recommended sexually transmitted disease screening of HIV-infected men who have sex with men.

Carter JW Jr, Hart-Cooper GD, Butler MO, Workowski KA, Hoover KW.

Sex Transm Dis. 2014 Feb;41(2):137-42. doi: 10.1097/OLQ.0000000000000067.

PMID:
24413496
47.

Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Butler MO, Hirano N.

Immunol Rev. 2014 Jan;257(1):191-209. doi: 10.1111/imr.12129. Review.

48.

Sexual behaviour and desire to discuss mental health as reported by HIV-infected men who have sex with men.

Safran MA, Hoover KW, Tao G, Butler MO.

Int J STD AIDS. 2013 Feb;24(2):93-9. doi: 10.1177/0956462412472307. Epub 2013 May 6.

PMID:
23514829
49.

Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help.

Butler MO, Imataki O, Yamashita Y, Tanaka M, Ansén S, Berezovskaya A, Metzler G, Milstein MI, Mooney MM, Murray AP, Mano H, Nadler LM, Hirano N.

PLoS One. 2012;7(1):e30229. doi: 10.1371/journal.pone.0030229. Epub 2012 Jan 12.

50.

IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells.

Imataki O, Ansén S, Tanaka M, Butler MO, Berezovskaya A, Milstein MI, Kuzushima K, Nadler LM, Hirano N.

J Immunol. 2012 Feb 15;188(4):1609-19. doi: 10.4049/jimmunol.1003446. Epub 2012 Jan 11.

Supplemental Content

Loading ...
Support Center